These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18256400)

  • 1. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions.
    Ingelman-Sundberg M
    N Engl J Med; 2008 Feb; 358(6):637-9. PubMed ID: 18256400
    [No Abstract]   [Full Text] [Related]  

  • 2. Abacavir hypersensitivity.
    Vandekerckhove L; Blot S; Vogelaers D
    N Engl J Med; 2008 Jun; 358(23):2514-5; author reply 2515-6. PubMed ID: 18525052
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacogenomics testing for type B adverse drug reactions to anti-infective drugs: the example of hypersensitivity to abacavir.
    Agundez JA; Esguevillas G; Amo G; Garcia-Martin E
    Recent Pat Antiinfect Drug Discov; 2014; 9(2):151. PubMed ID: 25891395
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients.
    Giorgini S; Martinelli C; Tognetti L; Carocci A; Giuntini R; Mastronardi V; Torricelli F; Leoncini F; Lotti T
    Dermatol Ther; 2011; 24(6):591-4. PubMed ID: 22515676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abacavir hypersensitivity reaction predicted by genetic test.
    AIDS Treat News; 2004 Mar; (399):6. PubMed ID: 15199868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-B*5701 screening for hypersensitivity to abacavir.
    Mallal S; Phillips E; Carosi G; Molina JM; Workman C; Tomazic J; Jägel-Guedes E; Rugina S; Kozyrev O; Cid JF; Hay P; Nolan D; Hughes S; Hughes A; Ryan S; Fitch N; Thorborn D; Benbow A;
    N Engl J Med; 2008 Feb; 358(6):568-79. PubMed ID: 18256392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility.
    Hughes AR; Spreen WR; Mosteller M; Warren LL; Lai EH; Brothers CH; Cox C; Nelsen AJ; Hughes S; Thorborn DE; Stancil B; Hetherington SV; Burns DK; Roses AD
    Pharmacogenomics J; 2008 Dec; 8(6):365-74. PubMed ID: 18332899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions.
    Airo P; Scarsi M; Malagoli A; Carella G; Izzo I; Carosi G; Torti C
    J Acquir Immune Defic Syndr; 2009 Jul; 51(3):361-2. PubMed ID: 19553774
    [No Abstract]   [Full Text] [Related]  

  • 9. Abacavir hypersensitivity.
    Abel S; Paturel L; Cabié A
    N Engl J Med; 2008 Jun; 358(23):2515; author reply 2515-6. PubMed ID: 18536095
    [No Abstract]   [Full Text] [Related]  

  • 10. Current trends in screening across ethnicities for hypersensitivity to abacavir.
    Rodriguez-Nóvoa S; Soriano V
    Pharmacogenomics; 2008 Oct; 9(10):1531-41. PubMed ID: 18855539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example.
    Hughes AR; Brothers CH; Mosteller M; Spreen WR; Burns DK
    Pharmacogenomics; 2009 Feb; 10(2):225-33. PubMed ID: 19207023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.
    Lucas A; Nolan D; Mallal S
    J Antimicrob Chemother; 2007 Apr; 59(4):591-3. PubMed ID: 17317695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complications and side effects. Abacavir hypersensitivity testing results--Montreal.
    TreatmentUpdate; 2007; 19(5):8-9. PubMed ID: 17955617
    [No Abstract]   [Full Text] [Related]  

  • 14. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.
    Hetherington S; Hughes AR; Mosteller M; Shortino D; Baker KL; Spreen W; Lai E; Davies K; Handley A; Dow DJ; Fling ME; Stocum M; Bowman C; Thurmond LM; Roses AD
    Lancet; 2002 Mar; 359(9312):1121-2. PubMed ID: 11943262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA-B*5701 Genotyping for Abacavir Prescription: Re-Examination of its Cost-Effectiveness in Singapore.
    Goh KS; Kapoor R; Lee CC; Ng CY; Leong KP
    Ann Acad Med Singap; 2019 Apr; 48(4):133-138. PubMed ID: 31131386
    [No Abstract]   [Full Text] [Related]  

  • 16. Labeling changes for abacavir.
    AIDS Patient Care STDS; 2008 Aug; 22(8):683-4. PubMed ID: 18721055
    [No Abstract]   [Full Text] [Related]  

  • 17. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?
    Phillips EJ
    Clin Infect Dis; 2006 Jul; 43(1):103-5. PubMed ID: 16758425
    [No Abstract]   [Full Text] [Related]  

  • 18. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.
    Waters LJ; Mandalia S; Gazzard B; Nelson M
    AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe abacavir hypersensitivity reaction in a patient tested HLA-B*5701 negative.
    Bonta PI; Vermeulen JN; Speelman P; Prins JM
    AIDS; 2008 Jul; 22(12):1522-3. PubMed ID: 18614879
    [No Abstract]   [Full Text] [Related]  

  • 20. [HLA-B*5701 and abacavir hypersensitivity reaction].
    Servonnet A; Leclercq E; Delacour H; Ceppa F
    Pathol Biol (Paris); 2010 Dec; 58(6):e95-100. PubMed ID: 19243901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.